Zusammenfassung
Da finanzielle Mittel in ihrer Höhe nur begrenzt zur Verfügung stehen, muss sich die Gesellschaft der Herausforderung stellen, eine gerechte und effektive sowie effiziente Gesundheitsversorgung anzubieten. Nur was der Gesellschaft einen Nutzen stiftet und was sie sich leisten kann, sollte nach herrschender Meinung im Rahmen einer solidarisch finanzierten Gesundheitsversorgung angeboten werden. Zielsetzung: Wenngleich eine stetige Reifung der Methodiken gesundheitsökonomischer Evaluationen festzustellen ist, bleibt bislang aber unklar, ab welchem Wert eine medizinische Maßnahme als kosteneffektiv gilt und solidarisch finanziert werden sollte. Vor diesem Hintergrund wird in diesem Beitrag das Kosteneffektivitätsschwellenwertkonzept erörtert. Methodik: Um der Beantwortung der Frage, was ein zusätzliches Lebensjahr oder qualitätskorrigiertes Lebensjahr (QALY) wert ist, nachgehen zu können, werden sechs verschiedene Ansätze zur Herleitung eines Kosteneffektivitätsschwellenwerts erläutert und diskutiert. Ergebnisse: Von diesen sechs Konzepten sind der Schattenpreisansatz und der Opportunitätskostenansatz als Ansätze zu verstehen, welchen eine explizite Budgetbeschränkung zugrunde liegt und welche die Definition eines optimalen Schwellenwerts zulassen. Für die verbleibenden vier Konzepte - Faustregeln, Vergleichskonzept, retrospektive Analyse sowie WTP-Ansatz - ist es typisch, dass diese Ansätze einen pseudooptimalen, also willkürlichen Schwellenwert liefern. Schlussfolgerung: Das Schattenpreiskonzept ist die evidenteste Methode, bei einem gegebenen Budget den medizinischen Nutzen zu maximieren. In diesem Zusammenhang ist im Interesse einer gerechten und effizienten Ressourcenallokation, eine Hinwendung von einer impliziten zu einer expliziten Rationierung zu fordern.
Abstract
Since modern healthcare systems are increasingly faced with financial restrictions and limitations, it is crucial to develop new approaches for ensuring equity, effectiveness and efficiency within the system. It is generally agreed that, in the scope of publicly funded healthcare, only services that are affordable and that will considerably benefit society should be offered. Objective: Although evalution methods in the field of healthcare economics are constantly progressing, the value at which a specific medical procedure can be considered cost-effective, and, therefore, should be publicly funded, still remains uncertain. With this as background, the cost-effectiveness threshold value concept will be discussed in this article. Methodology: In order to determine the value of a life year gained (LYG) or quality-adjusted life year (QALY), six different approaches to defining the cost-effectiveness threshold value will be introduced and discussed. Results: Two of these six approaches, the shadow-price concept and opportunity-cost concept, are based upon explicit budget constraints and permit the definition of an optimal threshold value. In contrast, the other four concepts - rule of thumb, comparison concept, retrospective analysis and the willingness-to-pay (WTP) approach - typically generate arbitrary pseudo-optimal thresholds. Conclusion: The shadow-price concept is the most evident method, given a fixed budget, to maximize the medical benefit. In this context, it appears that, in the interest of equitable and efficient resource allocation, a shift from implicit to explicit rationing is necessary.
Schlüsselwörter
Ressourcenallokation - Schwellenwert - Kosteneffektivitätsschwellenwert - Schattenpreiskonzept - Budgetbeschränkung
Key words
resource allocation - threshold value - cost-effectiveness threshold value - shadow-price concept - budget constraints
Literatur
1
Sendi P, Briggs A H.
Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane.
Health Economics.
2001;
10
675-680
2 World Health Organization (WHO). Commission on Macroeconomics and Health .Macroeconomics and Health: Investing in Health for economic development. Genf; WHO 2001
3
Coast J.
Who wants to know if their care is rationed? Views of citizens and service informants.
Health Expectations.
2001;
4
243-252
4
Eichler H G, Kong S X, Gerth W C. et al .
Use of Cost-Effectiveness Analysis in health-care resource allocation decision-making: How are Cost-Effectiveness thresholds expected to emerge?.
Value in Health.
2004;
7
518-528
5
Card W I, Mooney G H.
What is the menetary value of a human life?.
The British Medical Journal.
1977;
2
1627-1629
6
Weinstein M, Zeckhauser R.
Critical ratios and efficient allocation.
Journal of Public Economics.
1973;
2
147-157
7
Johannesson M, Weinstein M C.
On the decision rules of cost-effectiveness analysis.
Journal of Health Economics.
1993;
12
459-467
8
Anell A.
Priority setting for pharmaceuticals.
European Journal of Health Economics.
2004;
1
28-35
9
Karlsson G, Johannesson M.
The decision rules of Cost-Effectiveness Analysis.
PharmacoEconomics.
1996;
9
113-120
10
Kaplan R M, Bush J W.
Health-related quality of life measurement for evaluation research and policy analysis.
Health Psychology.
1982;
1
61-80
11
Laupacis A, Feeny D, Detsky A S. et al .
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
Canadian Medical Association Journal.
1992;
146
4, 473-481
12
Naylor C D, Williams J I, Basinski A. et al .
Technology assessment and cost-effectiveness analysis: Misguided guidelines?.
Canadian Medical Association Journal.
1993;
148
6, 921-924
13
Pyne J M, Rost K M, Zhang M. et al .
Cost-effectiveness of a primary care depression intervention.
Journal of General Internal Medicine.
2003;
18
432-441
14
Chapman R H, Berger M, Weinstein M C. et al .
When does quality-adjusted life-years matter in cost-effectiveness analysis?.
Health Economics.
2004;
13
429-436
15
Owens D K.
Interpretation of Cost-Effectiveness Analysis.
Journal of General Internal Medicine.
1998;
13
10, 716
16 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) .Methoden. Köln; IQWIG 2005
17
Horowitz N S, Gibb R K, Menegakis N E. et al .
Utility and Cost-Effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
Obstetrics and Gynecology.
2002;
99
5, 771-776
18
Martin S C, Gagnon D D, Zhang Z. et al .
Cost-Utility Analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
PharmacoEconomics.
2003;
21
16, 1153-1169
19
McIntosh E DG, Conway P, Willingham J. et al .
The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococal conjugate vaccine.
Vaccine.
2003;
21
2564-2572
20 Garber A M, Phelps C E. Economic foundations of Cost-Effectiveness Analysis. Cambridge; 1992
21 World Health Organization (WHO) .The World Health Report 2002. Genf; WHO 2002
22
Laupacis A, Feeny D, Detsky A S. et al .
Tentative guidelines for using clinical and economic evaluations revisited.
Canadian Medical Association Journal.
1993;
148
6, 927-929
23 Weinstein M C. From cost-effectiveness ratios to resource allocation: Where to draw the line?. Sloan FA Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies Cambridge; Cambridge University Press 1995: 77-97
24
Sendi P, Al M J, Gafni A. et al .
Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Social, Science and Medicine.
2003;
57
2207-2215
25 Culyer T. Introduction: Ought NICE to have a cost-effectiveness threshold?. Towse A, Pritchard C, Devlin N Cost-Effectiveness thresholds: Economic and ethical issues London; King's Fund 2002: 9-14
26
Raftery J.
NICE: faster access to modern treatments? Analysis of guidance on health technologies.
The British Medical Journal.
2001;
323
1300-1303
27
Rothgang H, Niebuhr D, Wasem J. et al .
Das National Institute for Clinical Excellence (NICE) - Staatsmedizinisches Rationierungsinstrument oder Vorbild für die evidenzbasierte Bewertung medizinischer Leistungen?.
Gesundheitswesen.
2004;
66
303-310
28
Towse A, Pritchard C.
National Institute for Clinical Excellence (NICE): Is economic appraisal working?.
PharmacoEconomics.
2002;
20
3, 95-105
29 Towse A, Pritchard C. Does NICE have a threshold? An external view. Towse A, Pritchard C, Devlin N Cost-Effectiveness thresholds: Economic and ethical issues London; King's Fund 2002: 25 - 30
30
National Institute for Clinical Excellence (NICE) .
Correction of factual inaccuracies and process misunderstandings.
Stand 31. 7.2005;
, http://www.nice.org.uk/pdf/PaperTwo.pdf
31 Littlejohns P. Does NICE have a threshold? A response. Towse A, Pritchard C, Devlin N Cost-Effectiveness thresholds: Economic and ethical issues London; King's Fund 2002: 31-37
32
National Institute for Clinical Excellence (NICE) .
Guidance on the use of orlistat for the treatment of obesity in adults, technology appraisal guidance No. 22.
Stand 31.7.2005;
, http://www.nice.org.uk/pdf/orlistatguidance.pdf
33 Towse A, Pritchard C, Devlin N. Cost-Effectiveness thresholds: Economic and ethical issues. London; King's Fund 2002
34
Devlin N, Parkin D.
Does NICE have a cost-effectiveness threshold and what other factores influence its decisions? A binary choice analysis.
Health Economics.
2004;
13
437-452
35 Breyer F, Zweifel P, Kifmann M. Gesundheitsökonomie. Berlin; Springer 2005
36 Johansson P O. Evaluating health risks: An economic approach. Cambridge; Cambridge University Press 1995
37 Pauly M V. Valuing health care benefits in money terms. Sloan FA Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies Cambridge; Cambridge University Press 1995: 99-124
38
Birch S, Gafni A.
Cost effectiveness/utility analysis: Do current decision rules lead us to where we want to be?.
Journal of Health Economics.
1992;
11
279-296
39 Richardson J. The role of willingness-to-pay in resource allocation in a national health scheme. West Heidelberg; CHPE 1999
40
Al M J, Feenstra T, Brouwer W BF.
Decision makers’ views on health care objectives and budget constraints: results from a pilot study.
Health Policy.
2004;
70
33-48
41 Greiner W, Schöffski O. Grundprinzipien einer Wirtschaftlichkeitsuntersuchung. Schöffski O, Schulenburg JMG vd Gesundheitsökonomische Evaluationen Berlin; Springer 205-229
42 Kriedel T. Effizienzanalysen von Gesundheitsprojekten: Diskussion und Anwendung auf Epilepsieambulanzen. Berlin; Springer 1980
43 Richardson J. Returns on investment in public health: Comments on the report by applied economics. West Heidelberg; CHPE 2004
44
Tengs T O, Adams M E, Plinskin J S. et al .
Five-hundred life-saving interventions and their cost-effectiveness.
Risk Analysis.
1995;
15
3, 369-390
45
Ramsberg J AK, Sjoberg L.
The cost-effectivenss of lifesaving interventions in Sweden.
Risk Analysis.
1997;
17
467-478
46 Loomes G. Valuing life years and QALYs: Transferability and convertibility of values across the UK public sector. Towse A, Pritchard C, Devlin N Cost-Effectiveness thresholds: Economic and ethical issues London; King's Fund 2002: 46-55
47
Claxton K.
The irrelevance of inference: a decision-making approach to the stochastic evalution of health care technologies.
Journal of Health Economics.
1999;
18
341-364
48
Sendi P, Gafni A, Birch S.
Opportunity cost and uncertainty in the economic evaluation of health care interventions.
Health Economics.
2002;
11
23-31
49 Torrance G W, Siegel J E, Luce B R. Framing and designing the cost-effectiveness analysis. Gold MR, Siegel JE., Russell LB et al Cost-effectiveness in health and medicine New York; Oxford University Press 1996: 54-81
50
Doyal L.
The rationing debate: Rationing within the NHS should be explicit: The case for.
The British Medical Journal.
1997;
314
1114
51 Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht; Kluwer Academic Publishers 1996
52
Gafni A, Birch S.
Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem.
Canadian Medical Association Journal.
1993;
148
6, 913-917
53
Johannesson M, Meltzer D, O’Conner R M.
Incorporating future costs in medical Cost-Effectiveness Analysis: Implications for the Cost-Effectiveness of treatment of hypertension.
Medical Decision Making.
1997;
17
382-389
54 Drummond M F, O’Brien B, Stoddart G L. et al .Methods for the economic evaluation of health care programmes. Oxford; Oxford University Press 1997
Prof. Dr. Oliver Schöffski, MPH
Lehrstuhl für Betriebswirtschaftslehre, insbesondere Gesundheitsmanagement, Fakultät für Wirtschafts- und Sozialwissenschaften, Friedrich-Alexander-Universität Erlangen-Nürnberg
Lange Gasse 20
90403 Nürnberg
Email: oliver.schoeffski@wiso.uni-erlangen.de